Objective: To test for baseline prostate cancer characteristics and survival differences after salvage radical prostatectomy (SRP) across 18 Surveillance, Epidemiology and End Results (SEER) registries from 2004 to 2016. Methods: We tabulated prostate-specific antigen (PSA), cT stage, age, and SRP rates across individual SEER registries. Kaplan–Meier and competing risks regression methodologies depicted cancer-specific mortality and other cause mortality. Finally, overall mortality was compared with predicted life expectancy. Results: Overall, 428 SRP patients (2004-2016) were identified in the SEER database. Median follow-up duration was 74 months (interquartile range [IQR], 31-114). The median age at diagnosis was 68 years (IQR, 61-73 years) with a median PSA at diagnosis of 8.8 ng/mL (IQR, 5.4-18.6 ng/mL) and 10% cT3-4 stage (0%-23.8%). Variability existed across individual SEER registries regarding age, PSA, cT stage, and annual number of SRPs (0-17), as well as cumulative numbers of SRPs (7-73) between 2004 and 2016. At 10 years, cancer-specific mortality was 23.2% vs. other cause mortality 19.3%. Finally, SRP patients exhibited higher 10-year overall mortality (43.3%) than predicted by life tables (31.8%). Conclusion: SRP is rarely performed. In most SEER registries, SRP use is very occasional. More than 2 average annual SRPs were reported in only 5 of all registries. Nonetheless, across all registries, SRP patients showed marginal to moderate differences in PSA, cT stage, and age at diagnosis. However, at 10 years of follow-up, 1 of 5 SRP patients died of other causes and observed overall mortality was higher than expected (36%).

Salvage Radical Prostatectomy: Baseline Prostate Cancer Characteristics and Survival Across SEER Registries / Wenzel, M.; Wurnschimmel, C.; Nocera, L.; Colla' Ruvolo, C.; Tian, Z.; Shariat, S. F.; Saad, F.; Briganti, A.; Graefen, M.; Becker, A.; Kluth, L. A.; Mandel, P.; Chun, F. K. H.; Karakiewicz, P. I.. - In: CLINICAL GENITOURINARY CANCER. - ISSN 1558-7673. - 19:4(2021), pp. e255-e263. [10.1016/j.clgc.2021.03.015]

Salvage Radical Prostatectomy: Baseline Prostate Cancer Characteristics and Survival Across SEER Registries

Colla' Ruvolo C.;Briganti A.;
2021

Abstract

Objective: To test for baseline prostate cancer characteristics and survival differences after salvage radical prostatectomy (SRP) across 18 Surveillance, Epidemiology and End Results (SEER) registries from 2004 to 2016. Methods: We tabulated prostate-specific antigen (PSA), cT stage, age, and SRP rates across individual SEER registries. Kaplan–Meier and competing risks regression methodologies depicted cancer-specific mortality and other cause mortality. Finally, overall mortality was compared with predicted life expectancy. Results: Overall, 428 SRP patients (2004-2016) were identified in the SEER database. Median follow-up duration was 74 months (interquartile range [IQR], 31-114). The median age at diagnosis was 68 years (IQR, 61-73 years) with a median PSA at diagnosis of 8.8 ng/mL (IQR, 5.4-18.6 ng/mL) and 10% cT3-4 stage (0%-23.8%). Variability existed across individual SEER registries regarding age, PSA, cT stage, and annual number of SRPs (0-17), as well as cumulative numbers of SRPs (7-73) between 2004 and 2016. At 10 years, cancer-specific mortality was 23.2% vs. other cause mortality 19.3%. Finally, SRP patients exhibited higher 10-year overall mortality (43.3%) than predicted by life tables (31.8%). Conclusion: SRP is rarely performed. In most SEER registries, SRP use is very occasional. More than 2 average annual SRPs were reported in only 5 of all registries. Nonetheless, across all registries, SRP patients showed marginal to moderate differences in PSA, cT stage, and age at diagnosis. However, at 10 years of follow-up, 1 of 5 SRP patients died of other causes and observed overall mortality was higher than expected (36%).
2021
Salvage Radical Prostatectomy: Baseline Prostate Cancer Characteristics and Survival Across SEER Registries / Wenzel, M.; Wurnschimmel, C.; Nocera, L.; Colla' Ruvolo, C.; Tian, Z.; Shariat, S. F.; Saad, F.; Briganti, A.; Graefen, M.; Becker, A.; Kluth, L. A.; Mandel, P.; Chun, F. K. H.; Karakiewicz, P. I.. - In: CLINICAL GENITOURINARY CANCER. - ISSN 1558-7673. - 19:4(2021), pp. e255-e263. [10.1016/j.clgc.2021.03.015]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/988783
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 7
social impact